[1]何文,董耀荣,陈兆善,等.强心方对扩张型临床心衰期心肌病患者心功能及血浆脑钠肽水平的影响[J].西部中医药,2013,26(07):4-7.
 HE Wen,DONG Yaorong,CHEN Zhaoshan,et al.Effects of QiangXin Prescription on Cardiac Function and Plasma Brain Natriuretic Peptide of Patients with Dilated Cardiomyopathy at the Stage of Heart Failure[J].Western Journal of Traditional Chinese Medicine,2013,26(07):4-7.
点击复制

强心方对扩张型临床心衰期心肌病患者心功能及血浆脑钠肽水平的影响
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年07期
页码:
4-7
栏目:
论著·临床论著
出版日期:
2013-07-15

文章信息/Info

Title:
Effects of QiangXin Prescription on Cardiac Function and Plasma Brain Natriuretic Peptide of Patients with Dilated Cardiomyopathy at the Stage of Heart Failure
文章编号:
1004-6852(2013)07-0004-04
作者:
何文董耀荣陈兆善胡坚文
上海市中医医院心内科,上海 200071
Author(s):
HE Wen DONG Yaorong CHEN Zhaoshan HU Jianwen
Department of Cardiology in Shanghai TCM Hospital, Shanghai 200071, China
关键词:
扩张型心肌病临床心衰期强心方NT-pro-BNP心室重构
Keywords:
dilated cardiomyopathy heart failure QiangXin prescription NT-pro-BNP ventricular remodeling
分类号:
R541
文献标志码:
A
摘要:
目的:观察强心方对扩张型临床心衰期心肌病患者血浆N-末端脑钠肽前体(NT-pro-BNP)水平的影响。方法:将60例临床心衰患者随机分为对照组和治疗组,每组30例。对照组给予西药常规治疗,根据病情选用血管紧张素转换酶抑制剂(ACEI)、血管紧张素Ⅱ的1型受体阻断剂(ARB)及β受体阻滞剂等;治疗组在对照组的基础上加用强心合剂煎服,1包/次,2次/d。2组均以连续治疗3个月为1个疗程,1个疗程后观察临床疗效、心超EF值及血浆NT-pro-BNP水平的变化。结果:强心方能显著改善患者肾虚症状积分(P<0.05),治疗后患者心输出量(CO)、每搏输出量(SV)、射血分数(EF)都有非常显著的升高(P<0.01),治疗组左室舒张末期内径(LVEDd)显著的缩短(P<0.05),同时神经体液因子血浆NT-pro-BNP的水平有非常显著的下降(P<0.01),其中NT-pro-BNP、EF较对照组有显著的统计学上的意义(P<0.05),而对照组作用不明显。结论:强心方可能通过加强临床心衰患者心脏的收缩功能、改善血流动力学(增加心输出量,提高射血分数)及调节神经体液因子(降低血浆NT-pro-BNP浓度),干预心室重构发生、发展,从而延缓心力衰竭的进程。
Abstract:
Objective: To observe the effects of QiangXin prescription on the level of plasma brain natriuretic peptide(BNP) of patients with dilated cardiomyopathy at the stage of heart failure. Method: All 60 patients were randomized into the control group and the treatment group, the control group were administered with routine western medicine, ACEI, ARB, beta receptor blockers and others were chosen according to the disease. The treatment group took QiangXin mixture, one package each time, water decocted and twice per day, three months were one course of treatment, clinical effects, EF index of echocardiogram and changes of plasma NT-pro-BNP were observed after one course of treatment. Result: QiangXin prescription could significantly improve the scores of kidney deficiency (P<0.05), after treating, cardiac output, stroke volume (SV) and ejection fraction (EF) were raised remarkably (P<0.01), left ventricular end diastolic diameter of the treatment group was shorten significantly (P<0.05), meanwhile the level of plasma was decreased remarkably (P<0.01), compared with the control group, NT-pro-BNP and EF showed significant statistical meaning(P<0.05), while the changes of the control group were subtle. Conclusion: QiangXin prescription could intervene the generation and development of ventricular remodeling through enhancing cardiac contraction of patients at the stage of heart failure, improving hemodynamics(increasing CO and improving EF) and regulating neuro-humoral factor(decreasing the concentrations of NT-pro-BNP) so that it could delay the process of heart failure.

备注/Memo

备注/Memo:
收稿日期:2013-03-04 作者简介:何文(1967—),女,博士学位。研究方向:慢性心力衰竭各期的中医药干预。
更新日期/Last Update: 2013-07-15